It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The experts ran through a carefully designed, detailed simulation of a new (fictional) viral illness called CAPS or coronavirus acute pulmonary syndrome. This was modeled after previous epidemics like SARS and MERS.
originally posted by: Bigbrooklyn
The coronavirus happens to have a patent on it.. Lab made and engineered..a reply to: TEOTWAWKIAIFF
FIELD OF THE INVENTION
The present invention relates to an attenuated coronavirus comprising a variant replicase gene, which causes the virus to have reduced pathogenicity. The present invention also relates to the use of such a coronavirus in a vaccine to prevent and/or treat a disease.
1. A live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or both of non-structural protein(s) nsp-10 and nsp-14, wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6, and/or wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7.
2. The coronavirus according to claim 1 wherein the variant replicase gene encodes a protein comprising one or more amino acid mutations selected from:
an amino acid mutation of Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; andan amino acid mutation of Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.
3. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.
4. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6; Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.
5. The coronavirus according to claim 1 wherein the replicase gene comprises at least one nucleotide substitutions selected from: compared to the sequence shown as SEQ ID NO: 1.
C to Tat nucleotide position 12137; andG to C at nucleotide position 18114;compared to the sequence shown as SEQ ID NO: 1;and optionally, comprises one or more nucleotide substitutions selected from T to A at nucleotide position 19047; andG to A at nucleotide position 20139;
6. The coronavirus according to claim 1 which is an infectious bronchitis virus (IBV).
7. The coronavirus according to claim 1 which is IBV M41.
8. The coronavirus according to claim 7, which comprises an S protein at least, part of which is from an IBV serotype other than M41.
9. The coronavirus according to claim 8, wherein the S1 subunit is from an IBV serotype other than M41.
10. The coronavirus according to claim 8, wherein the S protein is from an IBV serotype other than M41.
11. The coronavirus according to claim 1 which has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, wherein the virus is capable of replicating without being pathogenic to the embryo when administered to an embryonated egg.
12. A variant replicase gene as defined in claim 1.
13. A protein encoded by a variant coronavirus replicase gene according to claim 12.
14. A plasmid comprising a replicase gene according to claim 12.
15. A method for making the coronavirus according to claim 1 which comprises the following steps:
(i) transfecting a plasmid according to claim 14 into a host cell;(ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;(iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and(iv) selecting for recombining virus comprising the modified replicase gene.
16. The method according to claim 15, wherein the recombining virus is a vaccinia virus.
17. The method according to claim 15 which also includes the step:
(v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).
18. A cell capable of producing a coronavirus according to claim 1.
19. A vaccine comprising a coronavirus according to claim 1 and a pharmaceutically acceptable carrier.
20. A method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to claim 19 to the subject.
21. The method of claim 20, wherein the disease is infectious bronchitis (IB).
22. The method according to claim 20 wherein the method of administration is selected from the group consisting of; eye drop administration, intranasal administration, drinking water administration, post-hatch injection and in ovo injection.
23. The method according to claim 21 wherein the administration is in ovo vaccination.
24. A method for producing a vaccine according to claim 19, which comprises the step of infecting a cell according to claim 18 with a coronavirus according to claim 1.
25. The coronavirus according to claim 1, further comprising a mutation in one or both of nsp-15 and nsp-16.
originally posted by: flice
Firstly lets run up a few interesting coincidences:
- Wuhan, home to the only BSL-4 biolab in China
- China contacts WHO dec. 31st
- US CDC pinpoints market 24 hours later (?!)
- sars source was not found that fast
- Streets in Wuhan being smoked
- Doctors crying over number of patients
- As of jan 23: 25 dead and over 650 cases
Now to the point. Back in october 2019 Johns Hopkins held a joint event with the Gates that looked on how prepared we are for a pandemic event. How it would likely take place and how we would handle it.
Speed up to december 12.... Forbes decides to post an article about this event.
December 12/13 also happens to be the first day CV started spreading.
Just coincidences all of it??? Quite a few eh....
The new coronavirus rapidly spreading in China and nearby countries seems to trigger symptoms similar to those seen in the severe acute respiratory distress syndrome (SARS) coronavirus outbreak in 2003, two new studies show.
Published Jan. 24 in The Lancet journal, these are the first clinical studies conducted on patients struck by the new coronavirus, dubbed 2019-nCoV. As of Friday morning, there were 830 confirmed cases and 26 deaths in China tied to the coronavirus, which originated in the central Chinese city of Wuhan.
Similar to the 2003 SARS outbreak in China, most patients who came down with the Wuhan coronavirus were healthy, without any chronic underlying health issues. And symptoms also resembled those of SARS […]
All of the hospitalized patients had developed pneumonia, nearly all (98%) had a fever, three-quarters developed a cough, 44% felt fatigued, and 55% had some shortness of breath. Symptoms such as headache or diarrhea were rare, however.
On the other hand, "despite sharing some similar symptoms to SARS [such as fever, dry cough, shortness of breath], there are some important differences," Cao said in a Lancet news release.
For example, people with the new virus typically didn't have runny noses or other symptoms involving the upper respiratory tract, he said. And very few had intestinal symptoms such as diarrhea, which occurred in about a quarter of SARS patients.
Severe illness—enough to require admittance to the ICU—occurred in about a third of the hospitalized patients, Cao's team said, and six patients died.
Gene tests revealed that five of the family members carried a form of 2019-nCoV that had a type of protein allowing it to enter healthy cells. Yuen's team was also able to use samples from two patients to map the full genome of 2019-nCoV.
"With the improved surveillance network and laboratory capability developed following the SARS pandemic, China has now been able to recognize this new outbreak within a few weeks and has made the virus genome publicly available to help control its spread," said study co-author Dr. Rosana Wing-Shan Poon
The Johns Hopkins Center for Health Security in partnership with the World Economic Forum and the Bill and Melinda Gates Foundation hosted Event 201, a high-level pandemic exercise on October 18, 2019, in New York, NY. The purpose of the exercise was to illustrate the pandemic preparedness efforts, response decisions, and cooperation required from global businesses, governments, and public health leaders that the world will need to diminish the large-scale economic and societal consequences of a severe pandemic.
May 15, 2018
Biosafety and Biosecurity in the Era of Synthetic Biology: Meeting the Challenges in China and the United States
On Friday, July 26, 2019, the Johns Hopkins Center for Health Security and the Tianjin University Center for Biosafety Research and Strategy co-hosted an event that brought together leading experts and emerging leaders from China and the US to discuss the ways, both positive and negative, that synthetic biology may alter the social and economic frameworks of modern humanity.
July 26, 2019
Center news: August 14, 2019
The US Bioeconomy: Maximizing Opportunities for Economic Growth and National Security with Biology
On July 16, the Johns Hopkins Center for Health Security and Ginkgo Bioworks convened a meeting in Washington, DC, to solicit stakeholder input on specific ways that national policy can strengthen the US bioeconomy. The aims of the meeting were to consider the benefits to the US if its bioeconomy were to be expanded; examine the current health of the US bioeconomy; discuss existing US government programs, policies, and initiatives related to the bioeconomy; and identify priorities for strengthening the US bioeconomy.
July 16, 2019
Sofia Borges is the UN Foundation’s Senior Vice President and Head of the New York office. In this role, she serves as chief liaison with United Nations leadership and the diplomatic community
Professor George F. Gao is the Director-General, Chinese Center for Disease Control and Prevention; a Professor in the Institute of Microbiology, Chinese Academy of Sciences; President of the Chinese Society of Biotechnology; and President of the Asian Federation of Biotechnology (AFOB).
During the last administration, Dr. (Avril) Haines served as Assistant to the President and Principal Deputy National Security Advisor. She also served as the Deputy Director of the Central Intelligence Agency and Legal Adviser to the National Security Council.
(Infotainment background with major networks)
Hasti Taghi is the Executive Advisor to the Chairman of Advertising & Partnerships at NBCUniversal. In her role, she serves in a chief of staff capacity as a liaison between the executive team and the chairman. She also leads strategic initiatives for the office, including partnerships with the World Economic Forum.
The Event 201 scenario
Event 201 simulates an outbreak of a novel zoonotic coronavirus transmitted from bats to pigs to people that eventually becomes efficiently transmissible from person to person, leading to a severe pandemic. The pathogen and the disease it causes are modeled largely on SARS, but it is more transmissible in the community setting by people with mild symptoms.
Although at first some countries are able to control it, it continues to spread and be reintroduced, and eventually no country can maintain control.
There is no possibility of a vaccine being available in the first year. There is a fictional antiviral drug that can help the sick but not significantly limit spread of the disease.
The scenario ends at the 18-month point, with 65 million deaths.